
Modus Therapeutics
Swedish drug development company in clinical phase focused on normalizing the lives for patients with Sickle Cell Disease.
Market cap
$5.2m
Enterprise value
$5m
Share price
SEK1.20 MODTX.ST
Authorizing premium user...
Swedish drug development company in clinical phase focused on normalizing the lives for patients with Sickle Cell Disease.